EP2624818B1 - Mit borsäure stabilisierte bortezomib-formulierungen - Google Patents

Mit borsäure stabilisierte bortezomib-formulierungen Download PDF

Info

Publication number
EP2624818B1
EP2624818B1 EP11770615.0A EP11770615A EP2624818B1 EP 2624818 B1 EP2624818 B1 EP 2624818B1 EP 11770615 A EP11770615 A EP 11770615A EP 2624818 B1 EP2624818 B1 EP 2624818B1
Authority
EP
European Patent Office
Prior art keywords
bortezomib
boric acid
glycine
composition
mass ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP11770615.0A
Other languages
English (en)
French (fr)
Other versions
EP2624818A1 (de
Inventor
Arunya Usayapant
David Bowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi USA LLC
Original Assignee
Fresenius Kabi USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi USA LLC filed Critical Fresenius Kabi USA LLC
Publication of EP2624818A1 publication Critical patent/EP2624818A1/de
Application granted granted Critical
Publication of EP2624818B1 publication Critical patent/EP2624818B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • a lyophilized powder formed from 3.5 mg bortezomib dissolved in 5 mL t -butyl alcohol is reported as having impurity levels below 0.5% (relative to the bortezomib content) after storage for 1 week at 60°C in a closed container, at 40°C and 75% relative humidity, or at 25°C and 60% relative humidity.
  • WO 2009/154737 A1 discloses lyophilised bortezomib compositions containing glycine as bulking agent.
  • a method of making a solid composition that includes forming a liquid mixture including a solvent, bortezomib and boric acid, wherein the mass ratio of boric acid to bortezomib is from 2:1 to 10:1, and wherein the liquid mixture further comprises glycine, where the mass ratio of glycine to bortezomib is from 1:1 to 20:1, and lyophilizing the liquid mixture.
  • the solid composition included bortezomib, boric acid and glycine, with at most trace amounts of water and/or ethanol.
  • Cool water for injection (9 Liters, USP, 15°-30°C) was added to a clean compounding vessel covered with aluminum foil to protect the interior from light and then sparged with nitrogen until the dissolved oxygen level was below 2 parts per million (ppm).
  • Boric acid 51 grams was added to the water and mixed at room temperature (15°-30°C) until dissolved.
  • Glycine 150 grams was then added, and the liquid was mixed at room temperature until the glycine was dissolved. Approximately 1,500 mL of this solution was removed and reserved for use as a rinse solution.
  • Sparged water for injection was added to the compounding vessel to obtain a final volume of 12 liters, and the liquid was mixed for approximately 10 minutes. The mixture was pre-filtered through a 0.45 micron filter and subsequently through a 0.22 micron filter. Aliquots (2 mL) of the filtered solution were added to vials that were then partially stoppered.
  • the bortezomib compositions containing glycine and boric acid had substantially reduced reconstitution times relative to bortezomib compositions containing glycine alone.
  • a reduction in reconstitution time when boric acid was present also was observed for bortezomib compositions containing dextran or hydroxypropyl- ⁇ -cyclodextrin.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (14)

  1. Zusammensetzung, umfassend:
    Bortezomib und
    Borsäure;
    wobei die Zusammensetzung ein Feststoff ist, und
    das Massenverhältnis von Borsäure zu Bortezomib 2:1 bis 10:1 beträgt, wobei die Zusammensetzung ferner Glycin umfasst, wobei das Massenverhältnis von Glycin zu Bortezomib 1:1 bis 20:1 beträgt.
  2. Zusammensetzung nach Anspruch 1, wobei das Massenverhältnis von Borsäure zu Bortezomib 2:1 bis 4:1 oder 2:1 bis 3:1 beträgt.
  3. Zusammensetzung nach Anspruch 1 oder Anspruch 2, wobei das Massenverhältnis von Glycin zu Bortezomib 5:1 bis 15:1 oder 7:1 bis 10:1 beträgt.
  4. Zusammensetzung nach Anspruch 3, wobei das Massenverhältnis von Borsäure zu Bortezomib etwa 3:1 beträgt und das Massenverhältnis von Glycin zu Bortezomib etwa 7:1 beträgt.
  5. Zusammensetzung nach Anspruch 4, die etwa 3,5 mg Bortezomib, etwa 10,5 mg Borsäure und etwa 25 mg Glycin umfasst.
  6. Zusammensetzung nach Anspruch 1 oder Anspruch 2, ferner umfassend Mannit, wobei das Massenverhältnis von Mannit zu Bortezomib 1:1 bis 20:1 beträgt.
  7. Zusammensetzung nach einem der vorhergehenden Ansprüche, wobei mindestens ein Teil des Bortezomibs in der Zusammensetzung in einer Anhydridstruktur vorliegt oder mindestens ein Teil des Bortezomibs und der Borsäure zusammen in der Zusammensetzung in einer Anhydridstruktur vorliegen.
  8. Zusammensetzung nach einem der vorhergehenden Ansprüche, wobei, wenn die Zusammensetzung bei 55 °C gelagert wird, nach 3 Wochen höchstens 5 % des Bortezomibs zerfallen, nach 3 Wochen höchstens 2 % des Bortezomibs zerfallen, nach 3 Wochen höchstens 1 % des Bortezomibs zerfällt oder nach 3 Wochen höchstens 0,5 % des Bortezomibs zerfällt.
  9. Zusammensetzung nach einem der vorhergehenden Ansprüche, wobei die Zusammensetzung innerhalb von 4 Minuten, innerhalb von 3 Minuten, innerhalb von 1 Minute oder innerhalb von 30 Sekunden eine Lösung oder eine Emulsion bildet, wenn die Zusammensetzung in einer Bortezomib-Konzentration von 1 mg/ml Salzlösung mit einer 0,9 % NaCl-Salzlösung kombiniert und alle 15 Sekunden manuell geschüttelt wird.
  10. Verfahren zum Herstellen einer festen Zusammensetzung, umfassend:
    Bilden einer flüssigen Mischung, die ein Lösungsmittel, Bortezomib und Borsäure umfasst, wobei das Massenverhältnis von Borsäure zu Bortezomib 2:1 bis 10:1 beträgt, und wobei die flüssige Mischung ferner Glycin umfasst, wobei das Massenverhältnis von Glycin zu Bortezomib 1:1 bis 20:1 beträgt; und
    Lyophilisieren der flüssigen Mischung.
  11. Verfahren nach Anspruch 10, wobei das Lösungsmittel Wasser umfasst, und wobei das Lösungsmittel ferner 1 bis 20 Vol.% eines organischen Lösungsmittels und vorzugsweise 2 bis 10 Vol.% eines organischen Lösungsmittels oder etwa 5 Vol.% Ethanol umfasst.
  12. Verfahren nach Anspruch 10 oder Anspruch 11, wobei das Massenverhältnis von Borsäure zu Bortezomib 2:1 bis 4:1 oder 2:1 bis 3:1 beträgt.
  13. Verfahren nach einem der Ansprüche 10 bis 12, wobei das Massenverhältnis von Glycin zu Bortezomib in der flüssigen Mischung 5:1 bis 15:1 oder 7:1 bis 10:1 beträgt.
  14. Verfahren nach Anspruch 13, wobei das Massenverhältnis von Borsäure zu Bortezomib in der flüssigen Mischung etwa 3:1 beträgt, das Massenverhältnis von Glycin zu Bortezomib in der flüssigen Mischung etwa 7:1 beträgt und das Lösungsmittel Wasser und etwa 5 Vol.% Ethanol umfasst.
EP11770615.0A 2010-10-05 2011-10-04 Mit borsäure stabilisierte bortezomib-formulierungen Not-in-force EP2624818B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39004610P 2010-10-05 2010-10-05
PCT/US2011/054703 WO2012047845A1 (en) 2010-10-05 2011-10-04 Bortezomib formulations stabilised with boric

Publications (2)

Publication Number Publication Date
EP2624818A1 EP2624818A1 (de) 2013-08-14
EP2624818B1 true EP2624818B1 (de) 2017-04-05

Family

ID=44802402

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11770615.0A Not-in-force EP2624818B1 (de) 2010-10-05 2011-10-04 Mit borsäure stabilisierte bortezomib-formulierungen

Country Status (5)

Country Link
US (1) US8962572B2 (de)
EP (1) EP2624818B1 (de)
AU (1) AU2011312264B2 (de)
CA (1) CA2813003A1 (de)
WO (1) WO2012047845A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866135A1 (en) * 2012-03-02 2014-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
EA021179B1 (ru) * 2012-06-15 2015-04-30 Ощество С Ограниченной Ответственностью "Тева" Лиофилизат соединения бороновой кислоты
CN103070835B (zh) * 2013-01-31 2015-01-07 江苏奥赛康药业股份有限公司 一种含硼替佐米的冻干组合物及其制备方法
CN103142509B (zh) * 2013-03-06 2018-01-02 石药集团中奇制药技术（石家庄）有限公司 一种注射用硼替佐米药物组合物
CN103212055B (zh) * 2013-04-19 2014-11-05 海南锦瑞制药股份有限公司 一种硼替佐米的药物组合物及其制备方法
CN104414982B (zh) * 2013-08-28 2018-06-22 山东新时代药业有限公司 一种硼替佐米冻干粉针剂及其制备方法
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
WO2016001905A2 (en) * 2014-07-04 2016-01-07 Dr. Reddy’S Laboratories Limited Stable liquid ready-to-use injectable formulation of bortezomib
EP3031811A1 (de) 2014-12-09 2016-06-15 Teva Pharmaceuticals Ltd. Apfelsäureester aus Bortezomib
MA41505A (fr) * 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
CN105056205A (zh) * 2015-06-29 2015-11-18 杭州华东医药集团新药研究院有限公司 一种含硼替佐米的药物组合物及其制备方法
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
RU2659160C1 (ru) * 2017-07-10 2018-06-28 Акционерное Общество "Фарм-Синтез" Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом
CN109320584A (zh) * 2017-08-01 2019-02-12 重庆医药工业研究院有限责任公司 一种硼替佐米的杂质及其制备方法
BR112021016747A2 (pt) * 2019-02-28 2021-10-19 Ptc Therapeutics, Inc. Método para tratamento de um meloma múltiplo
CN110314221B (zh) * 2019-06-29 2020-09-04 四川汇宇制药股份有限公司 一种注射用硼替佐米的冻干工艺
WO2022094396A1 (en) * 2020-11-02 2022-05-05 Spes Pharmaceuticals Inc. Aqueous compositions of bortezomib
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435146C (en) * 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
WO2008075376A1 (en) 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
CN107266480A (zh) * 2008-06-17 2017-10-20 米伦纽姆医药公司 硼酸酯化合物及其医药组合物
WO2010039762A2 (en) * 2008-10-01 2010-04-08 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising boronic acid compounds
MX2011007192A (es) 2009-01-09 2011-10-04 Sun Pharma Advanced Res Co Ltd Composicion farmaceutica.
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
EP2238973A1 (de) 2009-04-07 2010-10-13 Cephalon France Lyophilisierte Präparate von Proteasominhibitoren
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
JP5661912B2 (ja) 2010-03-18 2015-01-28 イノファーマ，インコーポレイテッド 安定なボルテゾミブ製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP2624818A1 (de) 2013-08-14
CA2813003A1 (en) 2012-04-12
AU2011312264B2 (en) 2015-07-02
WO2012047845A1 (en) 2012-04-12
US20120083457A1 (en) 2012-04-05
AU2011312264A1 (en) 2013-05-09
US8962572B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
EP2624818B1 (de) Mit borsäure stabilisierte bortezomib-formulierungen
CA2234140C (fr) Formulation pharmaceutique lyophilisee stable
AU2019201392B2 (en) Methods for treatment of diseases
EA013324B1 (ru) Фармацевтические композиции бендамустина, предназначенные для лиофилизации
CH695185A5 (fr) Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame et procede pour leur production.
KR20130010902A (ko) 안정한 보르테조밉 포뮬레이션
JPH08500104A (ja) 結晶質アミホスチン組成物及びその調製方法並びに使用
KR20120016082A (ko) 프로테아좀 억제제의 동결건조 케이크
KR20110086583A (ko) 제8 인자 제형
US10253031B2 (en) Stable pemetrexed arginine salt and compositions comprising it
KR20110114562A (ko) 보르테조밉 함유 약학적 조성물
EP3218061B1 (de) Pharmazeutische carmustin-zusammensetzung
BG106578A (bg) Фармацевтични състави на фибринолитичен агент
EP2644189B1 (de) Stabile Bortezomibformulierungen
KR101844623B1 (ko) 안정성이 향상된 오타믹사반 제제
KR101807462B1 (ko) 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법
US20170035831A1 (en) Composition comprising bortezomib
JP6165986B2 (ja) ボルテゾミブを含む医薬組成物
OA13348A (fr) Composition pharmaceutique de vinflunine destinée à une administration parentérale, procédé de préparation et utilisation.
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
KR100725076B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물 함유 용액 및 제제
WO2014102755A1 (en) Bortezomib formulations
WO2016059515A1 (en) Bortezomib formulations
JP7423028B2 (ja) ボルテゾミブを含有する凍結乾燥医薬組成物
JP2001064199A (ja) レシチン化スーパーオキシドジスムターゼ含有医薬組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130409

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140710

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161018

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 881122

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011036693

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170405

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 881122

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170706

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170805

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011036693

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

26N No opposition filed

Effective date: 20180108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171004

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171004

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20111004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20211027

Year of fee payment: 11

Ref country code: DE

Payment date: 20211027

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20211025

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011036693

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221004